aVIDEX announces agreement with Active Biotech AB
Avidex announced an agreement with Active Biotech AB covering the use of Avidex's monoclonal T cell receptor (mTCR) technology to help Active to develop the cancer immunotherapeutic, Anyara (TTS). Avidex's mTCR product will be used by Active for product characterisation of Anyara during its clinical development. Commercial terms were not disclosed.
Active's Anyara cancer immunotherapeutic is a fusion protein of an antibody directed against 5T4 (an antigen found on solid tumours) and a molecule derived from a bacterial superantigen that stimulates T cells to kill the tumour cell. The optimised, second generation Anyara product is in Phase I clinical trials in non-small cell lung cancer patients in the US and Norway. A similar first generation candidate immunotherapeutic has already successfully concluded Phase II trials in renal and pancreatic cancer.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Researchers discover 'road map' in fish brain for how vertebrates produce sounds

Antec Scientific - Alphen aan den Rijn, Netherlands
Synthon enters into global license agreement with Amgen and Watson for biosimilar trastuzumab
Breakthrough model holds promise for treating Graves' disease - Animal model first to simulate eye complications of thyroid disorder
Cimzia (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
